Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 4% to reach the main end of the phase II clinical study of piconcibalizumab in the treatment of ulcerative colitis

Zhitongcaijing · 10/17 02:41

The Zhitong Finance App learned that Cinda Biotech (01801) rose more than 4%. As of press release, it had risen 3.99% to HK$45.6, with a turnover of HK$153 million.

According to the news, on October 17, Cinda Biotech announced that picontibimab injection (recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody, development code: IBI112) reached a major end in a multi-center, randomized, double-blind, placebo-controlled phase II clinical study conducted in Chinese subjects with moderate to severe active ulcerative colitis (UC).